NO20001828L - Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus - Google Patents

Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus

Info

Publication number
NO20001828L
NO20001828L NO20001828A NO20001828A NO20001828L NO 20001828 L NO20001828 L NO 20001828L NO 20001828 A NO20001828 A NO 20001828A NO 20001828 A NO20001828 A NO 20001828A NO 20001828 L NO20001828 L NO 20001828L
Authority
NO
Norway
Prior art keywords
tacrolimus
administration
patient
cyclosporin
pps
Prior art date
Application number
NO20001828A
Other languages
English (en)
Other versions
NO20001828D0 (no
Inventor
Gary E Striker
Lilliane Striker
Kenneth H Kortright
Original Assignee
Baker Norton Pharma
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma, Us Health filed Critical Baker Norton Pharma
Publication of NO20001828D0 publication Critical patent/NO20001828D0/no
Publication of NO20001828L publication Critical patent/NO20001828L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
NO20001828A 1997-10-09 2000-04-07 Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus NO20001828L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6294797P 1997-10-09 1997-10-09
US09/168,974 US6187745B1 (en) 1997-10-09 1998-10-01 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
PCT/US1998/021313 WO1999018961A1 (en) 1997-10-09 1998-10-09 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus

Publications (2)

Publication Number Publication Date
NO20001828D0 NO20001828D0 (no) 2000-04-07
NO20001828L true NO20001828L (no) 2000-05-15

Family

ID=22045901

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001828A NO20001828L (no) 1997-10-09 2000-04-07 Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus

Country Status (24)

Country Link
US (1) US6187745B1 (no)
EP (1) EP1027053B1 (no)
JP (1) JP2001519392A (no)
KR (1) KR100515196B1 (no)
CN (1) CN1154492C (no)
AT (1) ATE269098T1 (no)
AU (1) AU748495B2 (no)
BR (1) BR9813860A (no)
CA (1) CA2304374A1 (no)
CZ (1) CZ297440B6 (no)
DE (1) DE69824619T2 (no)
DK (1) DK1027053T3 (no)
ES (1) ES2221714T3 (no)
HK (1) HK1026845A1 (no)
HU (1) HUP0003904A3 (no)
IL (1) IL135235A0 (no)
NO (1) NO20001828L (no)
NZ (1) NZ503493A (no)
PL (1) PL191993B1 (no)
PT (1) PT1027053E (no)
RU (1) RU2191020C2 (no)
SK (1) SK285332B6 (no)
UA (1) UA65587C2 (no)
WO (1) WO1999018961A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035026A1 (es) 2000-01-19 2004-04-14 Baker Norton Pharma Uso de pentosan polisulfato en el tratamiento de ciertas condiciones de la prostata
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
IL160761A0 (en) * 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
CA2481184A1 (en) * 2002-04-16 2003-10-23 Masakazu Kobayashi Medicament for preventing and/or treating chronic rejection
EP2165711B1 (en) 2004-05-27 2014-05-21 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
WO2010020423A2 (en) 2008-08-22 2010-02-25 Baxter Healthcare S.A. Methods for treating bleeding disorders
EP2523553B1 (en) 2010-01-14 2020-04-08 Baxalta GmbH Methods and compositions for treating bleeding disorders
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
US8846620B2 (en) 2011-07-19 2014-09-30 Baxter International Inc. Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
WO2013052380A2 (en) * 2011-10-05 2013-04-11 Allergan, Inc. Compositions for enhancing nail health
EP3594686A3 (en) 2012-08-14 2020-04-08 Baxalta GmbH Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016199161A2 (en) * 2015-06-12 2016-12-15 Swati Vishal Jajodia A composition comprising pentosan polysulfate sodium for use in treatment of bladder outlet obstruction and/or lower urinary tract symptoms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466315A3 (en) 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) * 1995-02-03 1996-08-13 L T T Kenkyusho:Kk 腎不全治療剤
US5643892A (en) 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
EP1027053A1 (en) 2000-08-16
SK285332B6 (sk) 2006-11-03
HUP0003904A1 (hu) 2001-08-28
HK1026845A1 (en) 2000-12-29
PT1027053E (pt) 2004-09-30
NZ503493A (en) 2001-11-30
DE69824619D1 (de) 2004-07-22
AU748495B2 (en) 2002-06-06
AU9794398A (en) 1999-05-03
DE69824619T2 (de) 2005-06-23
RU2191020C2 (ru) 2002-10-20
ES2221714T3 (es) 2005-01-01
CZ20001274A3 (cs) 2001-12-12
KR20010030749A (ko) 2001-04-16
JP2001519392A (ja) 2001-10-23
PL191993B1 (pl) 2006-08-31
SK4672000A3 (en) 2001-09-11
EP1027053A4 (en) 2002-05-22
ATE269098T1 (de) 2004-07-15
DK1027053T3 (da) 2004-09-06
IL135235A0 (en) 2001-05-20
HUP0003904A3 (en) 2006-06-28
KR100515196B1 (ko) 2005-09-16
BR9813860A (pt) 2001-03-20
PL339774A1 (en) 2001-01-02
WO1999018961A1 (en) 1999-04-22
NO20001828D0 (no) 2000-04-07
CA2304374A1 (en) 1999-04-22
EP1027053B1 (en) 2004-06-16
CN1154492C (zh) 2004-06-23
US6187745B1 (en) 2001-02-13
CZ297440B6 (cs) 2006-12-13
CN1275080A (zh) 2000-11-29
UA65587C2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
AU642210B2 (en) Therapeutic use of indole-3-yl-carboxylic acid endo-8- methyl-8-aza-bicyclo(3,2,1)oct-3-yl ester
NO20001828L (no) Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus
MY125662A (en) Pharmaceutical formulations containing darifenacin
PL350313A1 (en) Apomorphine and sildenafil composition
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
JP2002523370A5 (no)
KR910019618A (ko) 발기부전증 치료용 제약 조성물
CA2274510A1 (en) Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
AU647463B2 (en) A method and a pharmaceutical preparation for treating pain
KR19980701720A (ko) 세스키테르펜 락톤 및 비타민 b 복합체를 함유하는 편두통 및 기타 질환 치료용 복합약
CA2537748A1 (en) Use of telmisartan for the prevention of vascular headache
EP0190851B1 (en) Improved antiinflammatory composition
Roy et al. Induction of theophylline toxicity and inhibition of clearance rates by ranitidine
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
BE1002255A5 (fr) Medicaments.
NL8105635A (nl) Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking.
NZ315632A (en) Process for preparing solid dosage forms of very low-dose drugs comprising admixing 1-3% by weight of carrier particles with a solution of drug in water
KR830008678A (ko) 진통 조성물
JPH0296521A (ja) 免疫性疾患治療剤
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней
JPH07188040A (ja) 鼻炎治療用組成物
Kissling et al. Efficacy and safety of SND 919, a new dopamine autoreceptor agonist in schizophrenia